# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Biora Therapeutics (NASDAQ:BIOR) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(...
Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it w...
Dosing of all patients in the trial has been successfully completed Final results are expected to be available in late Q2 2024S...
Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today announced the issua...
All pharmacokinetic endpoints were achieved, with a PK profile consistent with drug delivery and absorption in the colon All Na...
Shares of Nuvve Holding Corp. (NASDAQ: NVVE) fell sharply during Monday’s session after the company reported worse-than-expect...
Biora Therapeutics, Inc.